RA Capital Healthcare Fund LP's Form 4 filing
Tyra Biosciences, Inc. (TYRA) · filed Sep 17, 2021
- Accession no.
- 0001104659-21-116944
- Filed
- Sep 17, 2021, 4:34 PM ET
- Trade date
- Sep 17, 2021
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 4 non-derivative transactions and 5 derivative transactions. Open-market purchases total $20.0M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| RA Capital Healthcare Fund LPCIK 0001315082 | Director, 10% Owner |
| Ra Capital Management, L.P.CIK 0001346824 | Director, 10% Owner |
| Kolchinsky PeterCIK 0001384859 | Director, 10% Owner |
| Shah Rajeev M.CIK 0001619841 | Director, 10% Owner |
| RA Capital Nexus Fund, L.P.CIK 0001780117 | Director, 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | CConversionAcquired | +4,047,120 | –F1 | – | 4,047,120 | Indirect | |
| Sep 17, 2021 | Common Stock | PPurchaseAcquired | +1,250,000 | $16.00 | +$20,000,000 | 5,297,120 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionAcquired | +1,496,613 | –F1 | – | 1,496,613 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionAcquired | +442,721 | –F1 | – | 442,721 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 17, 2021 | Common Stock | CConversionDisposed | −2,626,932 | $0.00 | $0 | 0 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −1,023,219 | $0.00 | $0 | 0 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −442,721 | $0.00 | $0 | 0 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −1,420,188 | $0.00 | $0 | 0 | Indirect | |
| Sep 17, 2021 | Common Stock | CConversionDisposed | −473,394 | $0.00 | $0 | 0 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Referenced by the price of 3 transactions in Table I.
Remarks
Jake Simson, a Partner of the Adviser, serves on the Issuer's board of directors.